ATE230417T1 - Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien - Google Patents

Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien

Info

Publication number
ATE230417T1
ATE230417T1 AT97905136T AT97905136T ATE230417T1 AT E230417 T1 ATE230417 T1 AT E230417T1 AT 97905136 T AT97905136 T AT 97905136T AT 97905136 T AT97905136 T AT 97905136T AT E230417 T1 ATE230417 T1 AT E230417T1
Authority
AT
Austria
Prior art keywords
allergies
treatment
vaccination against
peptide immunogens
mimotope peptides
Prior art date
Application number
AT97905136T
Other languages
English (en)
Inventor
Franz Kricek
Beda Stadler
Original Assignee
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26308839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE230417(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9604412.8A external-priority patent/GB9604412D0/en
Priority claimed from GBGB9617702.7A external-priority patent/GB9617702D0/en
Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh
Application granted granted Critical
Publication of ATE230417T1 publication Critical patent/ATE230417T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/528CH4 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97905136T 1996-03-01 1997-02-28 Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien ATE230417T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9604412.8A GB9604412D0 (en) 1996-03-01 1996-03-01 Organic compounds
GBGB9617702.7A GB9617702D0 (en) 1996-08-22 1996-08-22 Organic compounds
PCT/EP1997/001013 WO1997031948A1 (en) 1996-03-01 1997-02-28 Peptide immunogens for vaccination against and treatment of allergy

Publications (1)

Publication Number Publication Date
ATE230417T1 true ATE230417T1 (de) 2003-01-15

Family

ID=26308839

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905136T ATE230417T1 (de) 1996-03-01 1997-02-28 Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien

Country Status (25)

Country Link
US (1) US6610297B1 (de)
EP (1) EP0885244B2 (de)
JP (2) JP3421970B2 (de)
KR (2) KR100498198B1 (de)
CN (1) CN1174998C (de)
AT (1) ATE230417T1 (de)
AU (1) AU719609B2 (de)
BR (1) BR9707819A (de)
CA (1) CA2245497C (de)
CY (1) CY2457B1 (de)
CZ (1) CZ299551B6 (de)
DE (1) DE69718150T3 (de)
DK (1) DK0885244T4 (de)
ES (1) ES2190799T5 (de)
HK (1) HK1014962A1 (de)
HU (1) HUP9901109A3 (de)
IL (1) IL125590A (de)
NO (1) NO321043B1 (de)
NZ (1) NZ331651A (de)
PL (1) PL187209B1 (de)
RU (1) RU2193413C2 (de)
SI (1) SI0885244T2 (de)
SK (1) SK284856B6 (de)
TR (1) TR199801722T2 (de)
WO (1) WO1997031948A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
EP1621209A3 (de) * 1998-11-02 2006-04-19 Resistentia Pharmaceuticals AB Vakzinen die auf Domänen von chimären Immunoglobulin E Peptide basieren
CN1193791C (zh) 1998-11-30 2005-03-23 希托斯生物技术股份公司 抗原的有序分子呈递,制备及使用的方法
IL145025A0 (en) * 1999-02-25 2002-06-30 Smithkline Beecham Biolog Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
JP2002537354A (ja) * 1999-02-25 2002-11-05 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ペプチド、及びH.influenzaeのプロテインD由来の担体を含む免疫原
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
AU5226201A (en) * 2000-04-13 2001-10-30 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US6887472B2 (en) 2000-08-30 2005-05-03 Pfizer Inc. Anti-IgE vaccines
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
ES2394293T3 (es) * 2001-02-28 2013-01-30 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vacuna contra cánceres que están asociados con el oncogén HER-2/neu
EP1239032A1 (de) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Milchsäurebakterien als Mitteln zur Behandlung und Vorbeugung von Allergie
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性IgEワクチン
WO2003015716A2 (en) 2001-08-13 2003-02-27 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
AU2003212215B9 (en) * 2002-01-15 2008-02-21 Bio Life Science Forschungs Und Entwicklungsges M.B.H. Oral vaccination
AU2003246690B2 (en) 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
BR0312792A (pt) 2002-07-19 2005-05-03 Cytos Biotechnology Ag Composições de vacinas contendo séries antigênicas de amilóide beta1-6
ATE536188T1 (de) 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
WO2005105106A2 (en) * 2004-04-21 2005-11-10 Roby Russell R Hormone treatment of macular degeneration
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
ITMI20052517A1 (it) * 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
PL2029173T3 (pl) 2006-06-26 2017-04-28 Macrogenics, Inc. Przeciwciała swoiste dla FC RIIB i sposoby ich zastosowania
EP2012122A1 (de) * 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
US8865179B2 (en) * 2008-01-26 2014-10-21 Swey-Shen Alexchen Aptameric IgE peptides in a protein scaffold as an allergy vaccine
KR101644221B1 (ko) 2008-12-09 2016-07-29 화이자 백신스 엘엘씨 IgE CH3 펩티드 백신
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
RU2761431C9 (ru) * 2020-10-26 2022-04-18 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Рекомбинантный полипептид на основе аллергена пыльцы березы и аллергена яблока в качестве вакцины от аллергии

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2602443A1 (de) 1975-04-04 1976-10-21 Univ California Biologisch aktive polypeptide
US4171299A (en) 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
EP0000252B1 (de) 1977-06-29 1982-02-03 Beecham Group Plc Peptiden, Verfahren zu dessen Herstellung und denen enthaltende pharmazeutische Präparate
JPS5944399A (ja) 1982-09-07 1984-03-12 Takeda Chem Ind Ltd 新規dna
GB8616166D0 (en) * 1986-07-02 1986-08-06 Research Corp Ltd Polypeptide competitor
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
EP0269455A3 (de) 1986-11-28 1989-09-06 Takeda Chemical Industries, Ltd. Hochgereinigtes Fusionsprotein, das ein menschliches IgE Fc-Fragment enthält, sowie dessen Herstellung
EP0344211A4 (de) 1987-02-20 1990-03-12 Imclone Systems Inc Monoklonale antikörper in impfstofformulierungen.
CA1336818C (en) 1987-04-16 1995-08-29 International Institute Of Cellular And Molecular Pathology Treatment of allergy and composition thereof
AU635492B2 (en) 1987-10-13 1993-03-25 Telik, Inc. Method to produce immunodiagnostic reagents
GB8727045D0 (en) 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5342924A (en) 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
GB8910263D0 (en) 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) * 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
DE69126607T2 (de) 1990-01-23 1998-01-15 Tanox Biosystems, Inc., Houston, Tex. Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
WO1991019001A1 (en) 1990-05-25 1991-12-12 British Technology Group Ltd Immunodiagnostic assay for rheumatoid arthritis
US5258289A (en) 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
GB9101550D0 (en) 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
DE122006000006I2 (de) * 1991-08-14 2011-06-16 Genentech Inc Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
GB9125024D0 (en) 1991-11-25 1992-01-22 Kirby Julian Rheumatoid arthritus treatment
JPH06113881A (ja) 1992-10-07 1994-04-26 Snow Brand Milk Prod Co Ltd ヒト型モノクローナル抗ペプチド抗体及びこれをコードするdna
DK0708656T3 (da) 1993-04-27 2002-12-02 United Biomedical Inc Antigene LHRH peptidkonstruktioner og universelle syntetiske immunstimulatorer til vacciner
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
WO1994026723A2 (en) 1993-05-14 1994-11-24 Genentech, Inc. ras FARNESYL TRANSFERASE INHIBITORS
GB9320897D0 (en) 1993-10-11 1993-12-01 Peptide Therapeutics Ltd Compounds useful in anti-allergy treatment
GB9324013D0 (en) * 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
FR2715304B1 (fr) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
WO1995026365A1 (en) * 1994-03-28 1995-10-05 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
AU3002695A (en) 1994-07-08 1996-02-09 King's College Ige antagonists
CA2203165A1 (en) 1994-10-25 1996-05-02 United Biomedical, Inc. Synthetic ige membrane anchor peptide immunogens for the treatment of allergy
AU6532498A (en) 1996-12-06 1998-06-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Inhibition of ige-mediated allergies by a human ige-derived oligopeptide
EP0955311A3 (de) 1998-04-09 2000-08-16 Idexx Laboratories, Inc. Peptidscher Impfstoff für Hundenallergie
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens

Also Published As

Publication number Publication date
ES2190799T5 (es) 2008-08-16
EP0885244B1 (de) 2003-01-02
CN1213380A (zh) 1999-04-07
JP2000502571A (ja) 2000-03-07
HUP9901109A2 (hu) 1999-07-28
SI0885244T1 (en) 2003-06-30
IL125590A0 (en) 1999-03-12
CA2245497C (en) 2009-02-24
NZ331651A (en) 2000-01-28
KR20050049509A (ko) 2005-05-25
SK118198A3 (en) 1999-03-12
JP3421970B2 (ja) 2003-06-30
US6610297B1 (en) 2003-08-26
TR199801722T2 (xx) 1998-12-21
RU2193413C2 (ru) 2002-11-27
ES2190799T3 (es) 2003-08-16
AU1879697A (en) 1997-09-16
IL125590A (en) 2001-08-26
DK0885244T3 (da) 2003-04-22
SK284856B6 (sk) 2006-01-05
AU719609B2 (en) 2000-05-11
CY2457B1 (en) 2005-06-03
DE69718150D1 (de) 2003-02-06
NO321043B1 (no) 2006-03-06
WO1997031948A1 (en) 1997-09-04
KR19990087425A (ko) 1999-12-27
DE69718150T2 (de) 2003-08-21
BR9707819A (pt) 1999-07-27
DE69718150T3 (de) 2009-03-05
PL187209B1 (pl) 2004-06-30
CA2245497A1 (en) 1997-09-04
PL328858A1 (en) 1999-03-01
EP0885244B2 (de) 2008-04-16
SI0885244T2 (sl) 2008-10-31
CZ277198A3 (cs) 1998-12-16
HUP9901109A3 (en) 1999-11-29
HK1014962A1 (en) 1999-10-08
NO983999L (no) 1998-11-02
CN1174998C (zh) 2004-11-10
DK0885244T4 (da) 2008-06-16
KR100584051B1 (ko) 2006-05-30
CZ299551B6 (cs) 2008-08-27
KR100498198B1 (ko) 2005-09-09
EP0885244A1 (de) 1998-12-23
JP2003231696A (ja) 2003-08-19
NO983999D0 (no) 1998-08-31

Similar Documents

Publication Publication Date Title
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
DE60221665D1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
CY1107578T1 (el) Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων
DE69533855D1 (de) UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
DE69912815D1 (de) Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien
DE69636285D1 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
DE69534325D1 (de) Peptide zur behandlung von krebs
DE69737067D1 (de) Vakzine zur behandlung von mycosen
DE69429101D1 (de) Verbindungen und zusammensetzungen zur behandlung von allergien und entzündungen
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DE69922364D1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE60037349D1 (de) Zusammensetzungen und Verfahren zur Behandlung von Tumoren

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0885244

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 0885244

Country of ref document: EP

REN Ceased due to non-payment of the annual fee